Skip to main content
. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593

Comparison 2. Donepezil (10mg/day) vs rivastigmine (3‐12 mg/day).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 MMSE mean change from baseline (ITT‐LOCF) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 24 months 1 955 Mean Difference (IV, Fixed, 95% CI) ‐0.5 [‐1.33, 0.33]
2 Activities of daily living (ADCS‐ADL) (ITT‐LOCF) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 24 months 1 929 Mean Difference (IV, Fixed, 95% CI) ‐2.08 [‐4.58, 0.42]
3 Behavioural disturbance (NPI‐10) (ITT‐LOCF) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 24 months 1 955 Mean Difference (IV, Fixed, 95% CI) 0.54 [‐1.68, 2.76]
4 Cognitive function (SIB) (ITT‐LOCF) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At 24 months 1 954 Mean Difference (IV, Fixed, 95% CI) ‐0.61 [‐3.66, 2.44]
5 Global Deterioration Scale (GDS) (ITT‐LOCF) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 At 24 months 1 954 Mean Difference (IV, Fixed, 95% CI) 0.11 [‐0.00, 0.22]
6 Total number of patients who withdrew before end of treatment 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
6.1 At 104 weeks 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.64 [0.50, 0.83]
7 Total number of patients who withdrew before end of treatment due to an adverse event 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
7.1 At 104 weeks 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.47 [0.32, 0.68]
8 Total number of patients who suffered an adverse event of nausea 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
8.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.37 [0.27, 0.50]
8.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 0.38 [0.23, 0.63]
9 Total number of patients who suffered an adverse event of vomiting 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.16 [0.10, 0.24]
9.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 0.25 [0.15, 0.43]
10 Total number of patients who suffered an adverse event of agitation 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 1.46 [0.93, 2.30]
10.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 1.26 [0.79, 2.00]
11 Total number of patients who suffered an adverse event of anorexia 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
11.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.42 [0.24, 0.72]
11.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 0.46 [0.24, 0.90]
12 Total number of patients who suffered an adverse event of diarrhoea 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
12.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.81 [0.50, 1.30]
12.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 1.03 [0.60, 1.77]
13 Total number of patients who suffered an adverse event of weight loss 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
13.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.28 [0.13, 0.61]
13.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 1.07 [0.67, 1.71]
14 Total number of patients who suffered an adverse event of headache 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
14.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.84 [0.47, 1.48]
14.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 0.82 [0.37, 1.81]
15 Total number of patients who suffered an adverse event of a fall 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
15.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.38 [0.18, 0.81]
15.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 1.21 [0.75, 1.94]
16 Total number of patients who suffered an adverse event of hypertension 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
16.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.34 [0.14, 0.81]
16.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 0.75 [0.40, 1.44]
17 Total number of patients who suffered an adverse event of depression 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
17.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 0.51 [0.24, 1.11]
17.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 0.67 [0.34, 1.30]
18 Total number of patients who suffered an adverse event of a urinary tract infection 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
18.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 1.63 [0.67, 3.96]
18.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 1.31 [0.70, 2.42]
19 Total number of patients who suffered an adverse event of aggression 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
19.1 By 16 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 1.57 [0.60, 4.09]
19.2 Between 16 and 104 weeks of treatment 1 857 Odds Ratio (M‐H, Fixed, 95% CI) 1.18 [0.64, 2.18]
20 Total number of patients who suffered a serious adverse event 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
20.1 At 104 weeks of treatment 1 994 Odds Ratio (M‐H, Fixed, 95% CI) 1.03 [0.79, 1.35]
21 Total number of patients who died before end of treatment 1   Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
21.1 At 104 weeks 1 994 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.32 [0.78, 2.22]